血液肿瘤患者血清促红素水平及临床意义  

Level of Serum Erythropoietin and Clinical Analysis in Patients with Hematologic Malignancies

作　　者：胡俊[1] 秦瑞[2] 毕向军[3] 

机构地区：[1]广东省惠州市中心人民医院血液科,516001 [2]广东省惠州市中心人民医院检验科,516001 [3]广州军区广州总医院肿瘤科,510010

出　　处：《实用全科医学》2007年第8期687-688,共2页Applied Journal Of General Practice

摘　　要：目的研究血液恶性肿瘤患者血清促红素(EPO)的水平以及患者对促红素的反应。方法应用放射免疫吸附方法分别检测血液系统恶性肿瘤患者、正常人、非癌性贫血患者的血清EPO水平,同时检测各组血红蛋白(Hb)、网织红细胞数。分析各组EPO水平差异及其与血红蛋白、网织红细胞数的相关性。结果血液恶性肿瘤患者血清EPO为(2.72±1.50)μg/L,网织红细胞为(2.60±0.98)%;正常对照组患者血清EPO为(1.59±0.69)μg/L,网织红细胞(1.17±0.35)%;非癌性贫血组患者血清EPO为(2.78±1.53)μg/L,网织红细胞为(5.46±2.12)%;血液肿瘤组患者与正常对照组患者比较,其血清EPO、Hb、网织红细胞值差异均有统计学意义(P<0.01);血液肿瘤患者与非癌性贫血组患者比较,网织红细胞检测结果、EPO和网织红细胞值的相关系数差异均有统计学意义(P<0.01)。结论血液肿瘤患者血清EPO水平较正常人高,但机体对EPO反应性弱,血液肿瘤患者的贫血可能与此有关。Objective To detect the level of serum erythropoietin in patients with hematologic malignancies（HM） and the response of patients to erythropoietin. Methods Serum erythropoietin levels were detected by ELISA in patients with HM, with non-cancer-related anemia and normal individuals. Hemoglobin （Hb） and reticulocyte were also detected in each group. Results The erythropoietin, hemoglobin and reticulocyte was （2.72 ± 1.50） μg/L, （87.20 ± 11.20） μg/L and （2.60 ± 0.98） % in patients with HM ; （ 1.59 ± 0.69） μg/L, （ 136. 1 ± 11.3 ） g/L and （ 1.17 ± 0.35 ） % in normal controls; （2.78 ± 1.53 ）μg/L, （90.5 ± 9.60） g/L and （5.46 ± 2.12） % in patients with non-cancer-related anemia, respectively. There was significant difference in the level of erythropoietin, hemoglobin and reticulocyte of patients with HM compared with normal control （P 〈0.01 ）. There was significant difference in the level of erythropoietin and hemoglobin between patients with HM and with noncancer-related anemia（P 〈 0.01 ）. Conclusions The level of erythropoietin of patients with HM was responsively increased but the reactivity of body to the erythropoietin was weakened. The anemia of patients with HM may be related to this result.

关 键 词：血液肿瘤 贫血 促红素 

分 类 号：R733[医药卫生—肿瘤]